State of the art in PEGylation: the great versatility achieved after forty years of research.

[1]  G. Borchard,et al.  Tryptophan-mPEGs: novel excipients that stabilize salmon calcitonin against aggregation by non-covalent PEGylation. , 2011, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[2]  K. Kiick,et al.  Tunable degradation of maleimide-thiol adducts in reducing environments. , 2011, Bioconjugate chemistry.

[3]  P. Giangrande,et al.  Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B. , 2011, Blood.

[4]  T. Nichols,et al.  Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide. , 2011, Blood.

[5]  Anna Mero,et al.  A new method to increase selectivity of transglutaminase mediated PEGylation of salmon calcitonin and human growth hormone. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[6]  Susan E. Cellitti,et al.  D-Ornithine coopts pyrrolysine biosynthesis to make and insert pyrroline-carboxy-lysine. , 2011, Nature chemical biology.

[7]  W. Sebald,et al.  N-terminal specificity of PEGylation of human bone morphogenetic protein-2 at acidic pH. , 2011, International journal of pharmaceutics.

[8]  Susan E. Cellitti,et al.  Site-specific protein modifications through pyrroline-carboxy-lysine residues , 2011, Proceedings of the National Academy of Sciences.

[9]  G. Cotton,et al.  Recombinant protein hydrazides: application to site-specific protein PEGylation. , 2011, Bioconjugate chemistry.

[10]  F. Veronese,et al.  Multivalent and Flexible PEG-Nitrilotriacetic Acid Derivatives for Non-covalent Protein Pegylation , 2011, Pharmaceutical Research.

[11]  R. Satchi‐Fainaro,et al.  Dendritic poly(ethylene glycol) bearing paclitaxel and alendronate for targeting bone neoplasms. , 2011, Molecular pharmaceutics.

[12]  B. E. Kimmel,et al.  Optimized clinical performance of growth hormone with an expanded genetic code , 2011, Proceedings of the National Academy of Sciences.

[13]  G. Borchard,et al.  Noncovalent pegylation by dansyl-poly(ethylene glycol)s as a new means against aggregation of salmon calcitonin. , 2011, Journal of pharmaceutical sciences.

[14]  Guifeng Zhang,et al.  Kinetic and stoichiometric analysis of the modification process for N-terminal PEGylation of staphylokinase. , 2011, Analytical biochemistry.

[15]  F. Veronese,et al.  Polyoxazoline: chemistry, properties, and applications in drug delivery. , 2011, Bioconjugate chemistry.

[16]  F. Metzger,et al.  Separation of Fast from Slow Anabolism by Site-specific PEGylation of Insulin-like Growth Factor I (IGF-I)* , 2011, The Journal of Biological Chemistry.

[17]  H. Ploegh,et al.  Sortase-catalyzed transformations that improve the properties of cytokines , 2011, Proceedings of the National Academy of Sciences.

[18]  James R. Baker,et al.  In Situ Maleimide Bridging of Disulfides and a New Approach to Protein PEGylation , 2011, Bioconjugate chemistry.

[19]  M. Vicent,et al.  Relevance of folic acid/polymer ratio in targeted PEG-epirubicin conjugates. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[20]  K. Maggon.  R&D Paradigm Shift and Billion‐Dollar Biologics , 2010 .

[21]  Gianfranco Pasut,et al.  PEG conjugates in clinical development or use as anticancer agents: an overview. , 2009, Advanced drug delivery reviews.

[22]  María J. Vicent,et al.  Combination therapy: opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines. , 2009, Advanced drug delivery reviews.

[23]  J. Kressler,et al.  Enzymatically catalyzed HES conjugation using microbial transglutaminase: Proof of feasibility. , 2009, Journal of pharmaceutical sciences.

[24]  R. J. Green,et al.  Polymer-drug conjugates for combination anticancer therapy: investigating the mechanism of action. , 2009, Journal of medicinal chemistry.

[25]  F. Veronese,et al.  PEGylation for improving the effectiveness of therapeutic biomolecules. , 2009, Drugs of today.

[26]  F. Veronese,et al.  A new PEG-beta-alanine active derivative for releasable protein conjugation. , 2008, Bioconjugate chemistry.

[27]  R. Bayer,et al.  Generation and biochemical characterization of glycoPEGylated factor VIIa derivatives , 2008, Thrombosis and Haemostasis.

[28]  F. Veronese,et al.  PEGylation: Posttranslational bioengineering of protein biotherapeutics. , 2008, Drug discovery today. Technologies.

[29]  N. Labrou,et al.  Chemical and genetic engineering strategies to improve the potency of pharmaceutical proteins and enzymes. , 2008, Current medicinal chemistry.

[30]  B. Manjula,et al.  PEGylation of human serum albumin: reaction of PEG-phenyl-isothiocyanate with protein. , 2008, Bioconjugate chemistry.

[31]  F. Veronese,et al.  Antitumoral activity of PEG-gemcitabine prodrugs targeted by folic acid. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[32]  Teruyuki Nagamune,et al.  Site‐Specific Protein Modification on Living Cells Catalyzed by Sortase , 2008, Chembiochem : a European journal of chemical biology.

[33]  Damon L. Meyer,et al.  Contribution of linker stability to the activities of anticancer immunoconjugates. , 2008, Bioconjugate chemistry.

[34]  F. Veronese,et al.  Synthesis and characterization of poly(2-ethyl 2-oxazoline)-conjugates with proteins and drugs: suitable alternatives to PEG-conjugates? , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[35]  F. Veronese,et al.  Site-specific modification and PEGylation of pharmaceutical proteins mediated by transglutaminase. , 2008, Advanced drug delivery reviews.

[36]  Francesco M Veronese,et al.  Anti-cancer PEG-enzymes: 30 years old, but still a current approach. , 2008, Advanced drug delivery reviews.

[37]  F. Veronese,et al.  Peptide and protein PEGylation III: advances in chemistry and clinical applications☆ , 2008 .

[38]  Mire Zloh,et al.  Disulfide bridge based PEGylation of proteins. , 2008, Advanced drug delivery reviews.

[39]  F. Perez-Ruiz,et al.  PEG-uricase in the management of treatment-resistant gout and hyperuricemia. , 2008, Advanced drug delivery reviews.

[40]  B. Sarmento,et al.  Lipid-based colloidal carriers for peptide and protein delivery – liposomes versus lipid nanoparticles , 2007, International journal of nanomedicine.

[41]  Hidde L Ploegh,et al.  Sortagging: a versatile method for protein labeling. , 2007, Nature chemical biology.

[42]  F. Veronese,et al.  Site-specific pegylation of G-CSF by reversible denaturation. , 2007, Bioconjugate chemistry.

[43]  F. Veronese,et al.  Cardiac safety and antitumoral activity of a new nitric oxide derivative of pegylated epirubicin in mice , 2007, Anti-cancer drugs.

[44]  Ajay P. Singh,et al.  Targeted Sialic Acid–Doxorubicin Prodrugs for Intracellular Delivery and Cancer Treatment , 2007, Pharmaceutical Research.

[45]  G. Pasut,et al.  Polymer-drug conjugation, recent achievements and general strategies , 2007 .

[46]  A. Almeida,et al.  Solid lipid nanoparticles as a drug delivery system for peptides and proteins. , 2007, Advanced drug delivery reviews.

[47]  A. Malavalli,et al.  Toxicity and hemodynamic effects after single dose administration of MalPEG-hemoglobin (MP4) in rhesus monkeys. , 2007, Translational research : the journal of laboratory and clinical medicine.

[48]  G. Pasut,et al.  New active poly(ethylene glycol) derivative for amino coupling , 2007 .

[49]  J. Tessmar,et al.  Matrices and scaffolds for protein delivery in tissue engineering. , 2007, Advanced drug delivery reviews.

[50]  David G. Longstaff,et al.  A natural genetic code expansion cassette enables transmissible biosynthesis and genetic encoding of pyrrolysine , 2007, Proceedings of the National Academy of Sciences.

[51]  Melissa C. Jones,et al.  Insulin detemir: a long-acting insulin product. , 2006, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[52]  R. Bayer,et al.  GlycoPEGylation of recombinant therapeutic proteins produced in Escherichia coli. , 2006, Glycobiology.

[53]  S. Brocchini,et al.  Site-specific PEGylation of native disulfide bonds in therapeutic proteins , 2006, Nature chemical biology.

[54]  F. Veiga,et al.  Nanoencapsulation II. Biomedical applications and current status of peptide and protein nanoparticulate delivery systems. , 2006, Nanomedicine : nanotechnology, biology, and medicine.

[55]  Hong Zhao,et al.  Structure-function engineering of interferon-beta-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation. , 2006, Bioconjugate chemistry.

[56]  F. Veronese,et al.  Nitric oxide modulates proapoptotic and antiapoptotic properties of chemotherapy agents: the case of NO‐pegylated epirubicin , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[57]  L. Marraffini,et al.  Sortases and the Art of Anchoring Proteins to the Envelopes of Gram-Positive Bacteria , 2006, Microbiology and Molecular Biology Reviews.

[58]  D. Filpula,et al.  Linear and branched bicin linkers for releasable PEGylation of macromolecules: controlled release in vivo and in vitro from mono- and multi-PEGylated proteins. , 2006, Bioconjugate chemistry.

[59]  D. Guyer,et al.  Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease , 2006, Nature Reviews Drug Discovery.

[60]  I. Macdougall.  CERA (Continuous Erythropoietin Receptor Activator): a new erythropoiesis-stimulating agent for the treatment of anemia. , 2005, Current hematology reports.

[61]  Claudia Fruijtier-Pölloth.  Safety assessment on polyethylene glycols (PEGs) and their derivatives as used in cosmetic products. , 2005, Toxicology.

[62]  G. Gregoriadis,et al.  Improving the therapeutic efficacy of peptides and proteins: a role for polysialic acids. , 2005, International journal of pharmaceutics.

[63]  Yan Zhang,et al.  Pyrrolysine and Selenocysteine Use Dissimilar Decoding Strategies* , 2005, Journal of Biological Chemistry.

[64]  F. Veronese,et al.  PEG-doxorubicin conjugates: influence of polymer structure on drug release, in vitro cytotoxicity, biodistribution, and antitumor activity. , 2005, Bioconjugate chemistry.

[65]  H. Senn,et al.  Structural and biophysical characterization of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers. , 2005, Bioconjugate chemistry.

[66]  F. Veronese,et al.  PEG-epirubicin Conjugates with High Drug Loading , 2005 .

[67]  F. Veronese,et al.  Poly(ethylene glycol)-poly(ester-carbonate) block copolymers carrying PEG-peptidyl-doxorubicin pendant side chains: synthesis and evaluation as anticancer conjugates. , 2005, Biomacromolecules.

[68]  P. Schultz,et al.  Site-specific PEGylation of proteins containing unnatural amino acids. , 2004, Bioorganic & medicinal chemistry letters.

[69]  J. V. Van Alstine,et al.  Prediction of the viscosity radius and the size exclusion chromatography behavior of PEGylated proteins. , 2004, Bioconjugate chemistry.

[70]  Y. Shechter,et al.  Prolonging the Action of Protein and Peptide Drugs by a Novel Approach of Reversible Polyethylene Glycol Modification* , 2004, Journal of Biological Chemistry.

[71]  Alessandra Semenzato,et al.  Specific antitumor targetable beta-cyclodextrin-poly(ethylene glycol)-folic acid drug delivery bioconjugate. , 2004, Bioconjugate chemistry.

[72]  I. Kola,et al.  Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.

[73]  F. Veronese,et al.  PEG-Ara-C conjugates for controlled release. , 2004, European journal of medicinal chemistry.

[74]  M. Graham.  Pegaspargase: a review of clinical studies. , 2003, Advanced drug delivery reviews.

[75]  P. Caliceti,et al.  Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. , 2003, Advanced drug delivery reviews.

[76]  S. Dharap,et al.  Molecular targeting of drug delivery systems to ovarian cancer by BH3 and LHRH peptides. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[77]  L. Buck,et al.  Enhancement of therapeutic protein in vivo activities through glycoengineering , 2003, Nature Biotechnology.

[78]  D. Filpula,et al.  Controlled release of proteins from their poly(ethylene glycol) conjugates: drug delivery systems employing 1,6-elimination. , 2003, Bioconjugate chemistry.

[79]  J. M. Harris,et al.  Effect of pegylation on pharmaceuticals , 2003, Nature Reviews Drug Discovery.

[80]  S. Aime,et al.  NMR structure of two novel polyethylene glycol conjugates of the human growth hormone-releasing factor, hGRF(1-29)-NH2. , 2003, Journal of the American Chemical Society.

[81]  Joel A Swanson,et al.  Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities. , 2003, Advanced drug delivery reviews.

[82]  T. Allen.  Ligand-targeted therapeutics in anticancer therapy , 2002, Nature Reviews Cancer.

[83]  D. Wyss,et al.  Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications. , 2002, Advanced drug delivery reviews.

[84]  S. W. Kim,et al.  Effects of PEG conjugation on insulin properties. , 2002, Advanced drug delivery reviews.

[85]  A. P. Chapman,et al.  PEGylated antibodies and antibody fragments for improved therapy: a review. , 2002, Advanced drug delivery reviews.

[86]  M. Treuheit,et al.  Mono-N-terminal poly(ethylene glycol)-protein conjugates. , 2002, Advanced drug delivery reviews.

[87]  M. Bentley,et al.  Chemistry for peptide and protein PEGylation. , 2002, Advanced drug delivery reviews.

[88]  S. Pedder,et al.  Use of peginterferon alfa-2a (40 KD) (Pegasys) for the treatment of hepatitis C. , 2002, Advanced drug delivery reviews.

[89]  H. Sato,et al.  Enzymatic procedure for site-specific pegylation of proteins. , 2002, Advanced drug delivery reviews.

[90]  Veronese Fm,et al.  Introduction and overview of peptide and protein pegylation. , 2002 .

[91]  Joseph A. Krzycki,et al.  Pyrrolysine Encoded by UAG in Archaea: Charging of a UAG-Decoding Specialized tRNA , 2002, Science.

[92]  M. Royzen,et al.  Anticancer drug delivery systems: multi-loaded N4-acyl poly(ethylene glycol) prodrugs of ara-C. II. Efficacy in ascites and solid tumors. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[93]  Yan-Hui Liu,et al.  Carboxyalkylated Histidine Is a pH-Dependent Product of Pegylation with SC-PEG , 2001, Pharmaceutical Research.

[94]  P G Schultz,et al.  Expanding the Genetic Code of Escherichia coli , 2001, Science.

[95]  D. Wyss,et al.  Identification of the major positional isomer of pegylated interferon alpha-2b. , 2000, Biochemistry.

[96]  M. S. Tewart,et al.  Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. , 2000 .

[97]  H. Maeda,et al.  Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[98]  F. Liu,et al.  Synthesis and characterization of poly(ethylene glycol)-insulin conjugates. , 2000, Bioconjugate chemistry.

[99]  M. Royzen,et al.  Drug delivery systems based on trimethyl lock lactonization: poly(ethylene glycol) prodrugs of amino-containing compounds. , 2000, Journal of medicinal chemistry.

[100]  S. Mazmanian,et al.  Purification and characterization of sortase, the transpeptidase that cleaves surface proteins of Staphylococcus aureus at the LPXTG motif. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[101]  G. Shopp,et al.  Short communication: renal tubular vacuolation in animals treated with polyethylene-glycol-conjugated proteins. , 1998, Toxicological sciences : an official journal of the Society of Toxicology.

[102]  J. Leonard,et al.  Effects of Single-Dose Interleukin-12 Exposure on Interleukin-12–Associated Toxicity and Interferon-γ Production , 1997 .

[103]  J. Israelachvili.  The different faces of poly(ethylene glycol). , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[104]  R. Shorr,et al.  Transitional vacuole formation following a bolus infusion of PEG-hemoglobin in the rat. , 1996, Artificial cells, blood substitutes, and immobilization biotechnology.

[105]  P. Schultz,et al.  Site-specific protein modification using a ketone handle , 1996 .

[106]  D. Brems,et al.  Characterization and Stability of N-terminally PEGylated rhG-CSF , 1996, Pharmaceutical Research.

[107]  D. Leckband,et al.  Direct Measurement of Polyethylene Glycol Induced Depletion Attraction between Lipid Bilayers , 1996 .

[108]  Y. Ikada,et al.  Fate of water-soluble polymers administered via different routes. , 1995, Journal of pharmaceutical sciences.

[109]  D. Leckband,et al.  Modulation of interaction forces between bilayers exposing short-chained ethylene oxide headgroups. , 1994, Biophysical journal.

[110]  Y. Ikada,et al.  Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration to mice. , 1994, Journal of pharmaceutical sciences.

[111]  T. Arakawa,et al.  Cysteine 17 of recombinant human granulocyte-colony stimulating factor is partially solvent-exposed , 1993, Journal of protein chemistry.

[112]  R. Rice,et al.  Transglutaminases: multifunctional cross‐linking enzymes that stabilize tissues , 1991, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[113]  K. Petrak,et al.  Transport of macromolecules across the capillary walls , 1989 .

[114]  D. Hoekstra,et al.  Effect of poly(ethylene glycol) on the Ca2+-induced fusion of didodecyl phosphate vesicles. , 1988, Biochemistry.

[115]  M. Hershfield,et al.  Adenosine deaminase deficiency with late onset of recurrent infections: response to treatment with polyethylene glycol-modified adenosine deaminase. , 1988, The Journal of pediatrics.

[116]  W. M. Linehan,et al.  A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. , 1987, The New England journal of medicine.

[117]  P. Luckham,et al.  Variation of effective adsorbed polymer layer thickness with molecular weight in good and poor solvents , 1986 .

[118]  P. Luckham,et al.  Interactions between smooth solid surfaces in solutions of adsorbing and nonadsorbing polymers in good solvent conditions , 1985 .

[119]  F. Davis,et al.  Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. , 1977, The Journal of biological chemistry.

[120]  F. Davis,et al.  Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. , 1977, The Journal of biological chemistry.

[121]  Chee-Youb Won,et al.  PEG-modified biopharmaceuticals. , 2009, Expert opinion on drug delivery.

[122]  A. Nesbitt,et al.  Certolizumab pegol: a PEGylated anti-tumour necrosis factor alpha biological agent , 2009 .

[123]  H. M. Nielsen,et al.  Delivery technologies for biopharmaceuticals : peptides, proteins, nucleic acids and vaccines , 2009 .

[124]  F. Veronese,et al.  PEGylated Protein Drugs: Basic Science and Clinical Applications , 2009 .

[125]  J. Jazayeri,et al.  Fc-based cytokines : prospects for engineering superior therapeutics. , 2008, BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy.

[126]  David E. Golan,et al.  Protein therapeutics: a summary and pharmacological classification , 2008, Nature Reviews Drug Discovery.

[127]  David J Brayden,et al.  Advances in PEGylation of important biotech molecules: delivery aspects. , 2008, Expert opinion on drug delivery.

[128]  S. Brocchini,et al.  Site-specific PEGylation of protein disulfide bonds using a three-carbon bridge. , 2007, Bioconjugate chemistry.

[129]  T. P. Stewart,et al.  Alterations in phospholipid polymorphism by polyethylene glycol , 2005, The Journal of Membrane Biology.

[130]  T. P. Stewart,et al.  Lipid-polyethylene glycol interactions: II. Formation of defects in bilayers , 2005, The Journal of Membrane Biology.

[131]  T. P. Stewart,et al.  Lipid-polyethylene glycol interactions: I. Induction of fusion between liposomes , 2005, The Journal of Membrane Biology.

[132]  T. Taguchi,et al.  Phase I study of recombinant human tumor necrosis factor , 2004, Cancer Chemotherapy and Pharmacology.

[133]  J. A. Scarlett,et al.  Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. , 2000, The New England journal of medicine.

[134]  J. Leonard,et al.  Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. , 1997, Blood.

[135]  M. Nucci,et al.  The physiological and histopathological response of dogs to exchange transfusion with polyethylene glycol-modified bovine hemoglobin (PEG-Hb). , 1996, Artificial cells, blood substitutes, and immobilization biotechnology.

[136]  P. Caliceti,et al.  A branched monomethoxypoly(ethylene glycol) for protein modification. , 1995, Bioconjugate chemistry.

[137]  J. M. Harris,et al.  Poly(Ethylene Glycol) Chemistry Biotechnical and Biomedical Applications , 1992 .